RMTI has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
RMTI has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Rockwell Medical's Average Total Inventories for the quarter that ended in Sep. 2024 was $5.89 Mil. Rockwell Medical's Revenue for the three months ended in Sep. 2024 was $28.32 Mil. Rockwell Medical's Inventory-to-Revenue for the quarter that ended in Sep. 2024 was 0.21.
Rockwell Medical's Inventory-to-Revenue for the quarter that ended in Sep. 2024 declined from Jun. 2024 (0.23) to Jun. 2024 (0.21)
A decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:
1. investment in inventory is shrinking in relation to revenueDays Inventory indicates the number of days of goods in sales that a company has in the inventory. Rockwell Medical's Days Inventory for the three months ended in Sep. 2024 was 24.33.
Inventory Turnover measures how fast the company turns over its inventory within a year. Rockwell Medical's Inventory Turnover for the quarter that ended in Sep. 2024 was 3.75.
The historical data trend for Rockwell Medical's Inventory-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rockwell Medical Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Inventory-to-Revenue | Get a 7-Day Free Trial | 0.06 | 0.06 | 0.06 | 0.07 | 0.07 |
Rockwell Medical Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Inventory-to-Revenue | Get a 7-Day Free Trial | 0.24 | 0.26 | 0.26 | 0.23 | 0.21 |
For the Drug Manufacturers - Specialty & Generic subindustry, Rockwell Medical's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Rockwell Medical's Inventory-to-Revenue distribution charts can be found below:
* The bar in red indicates where Rockwell Medical's Inventory-to-Revenue falls into.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Rockwell Medical's Inventory-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as
Inventory-to-Revenue (A: Dec. 2023 ) | |||||||
= | Average Total Inventories | / | Revenue | ||||
= | ( (Total Inventories (A: Dec. 2022 ) | + | Total Inventories (A: Dec. 2023 )) | / | count ) | / | Revenue (A: Dec. 2023 ) |
= | ( (5.814 | + | 5.871) | / | 2 ) | / | 83.612 |
= | 5.8425 | / | 83.612 | ||||
= | 0.07 |
Rockwell Medical's Inventory-to-Revenue for the quarter that ended in Sep. 2024 is calculated as
Inventory-to-Revenue (Q: Sep. 2024 ) | |||||||
= | Average Total Inventories | / | Revenue | ||||
= | ( (Total Inventories (Q: Jun. 2024 ) | + | Total Inventories (Q: Sep. 2024 )) | / | count ) | / | Revenue (Q: Sep. 2024 ) |
= | ( (5.883 | + | 5.888) | / | 2 ) | / | 28.316 |
= | 5.8855 | / | 28.316 | ||||
= | 0.21 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rockwell Medical (NAS:RMTI) Inventory-to-Revenue Explanation
An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:
1. investment in inventory is growing more rapidly than revenueLikewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:
1. investment in inventory is shrinking in relation to revenueMore Related Terms:
1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Rockwell Medical's Days Inventory for the three months ended in Sep. 2024 is calculated as:
Days Inventory | = | Average Total Inventories (Q: Sep. 2024 ) | / | Cost of Goods Sold (Q: Sep. 2024 ) | * | Days in Period |
= | 5.8855 | / | 22.077 | * | 365 / 4 | |
= | 24.33 |
2. Inventory Turnover measures how fast the company turns over its inventory within a year.
Rockwell Medical's Inventory Turnover for the quarter that ended in Sep. 2024 is calculated as
Inventory Turnover | = | Cost of Goods Sold (Q: Sep. 2024 ) | / | Average Total Inventories (Q: Sep. 2024 ) |
= | 22.077 | / | 5.8855 | |
= | 3.75 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Rockwell Medical's Inventory-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Mark H Ravich | other: See Footnote 1 | |
Mark Strobeck | director, officer: President and CEO | 460 EAST SWEDESFORD ROAD, SUITE 1050, WAYNE PA 19087 |
Jesse Neri | officer: SVP, FINANCE | 851 DUPORTAIL ROAD, SECOND FLOOR, CHESTERBROOK PA 19087 |
Joan Lau | director | C/O RENOVACOR, INC., 5 MEAD POINT DRIVE, GREENWICH CT 06830 |
Russell Skibsted | officer: See Remarks | 15 TRANQUILITY PLACE, LADERA RANCH CA 92694 |
Megan C. Timmins | officer: SVP, General Counsel | 600 LEE ROAD, SUITE 100, WAYNE PA 19087 |
Allen Nissenson | director | 601 HAWAII ST., EL SEGUNDO CA 90245 |
Robert S Radie | director | 101 LINDENWOOD DRIVE, SUITE 225, MALVERN PA 19355 |
Andrea Heslin Smiley | director | 600 LEE ROAD, SUITE 100, WAYNE PA 19087 |
David S. Richmond | 10 percent owner, other: See Footnote 1 | 3568 WILDWOOD AVENUE, JACKSON MI 49202 |
Russell H Ellison | director | 270 RIVERSIDE DR., APT. 12D, NEW YORK NY 10025 |
Marc L Hoffman | officer: Chief Medical Officer | 30142 WIXOM ROAD, WIXOM MI 48393 |
John Peter Mclaughlin | director | C/O PDL BIOPHARMA, INC., 932 SOUTHWOOD BOULEVARD, INCLINE VILLAGE NV 89451 |
Richmond Brothers, Inc. | 10 percent owner, other: See Footnote 1 | 7415 FOXWORTH COURT, JACKSON MI 49201 |
Stuart M Paul | director, officer: Chief Executive Officer | HOME DIAGNOSTICS, INC., 2400 NW 55TH COURT, FORT LAUDERDALE FL 33309 |
From GuruFocus
By GuruFocus Research • 05-15-2024
By GuruFocus News • 11-11-2024
By Business Wire • 03-25-2024
By Business Wire • 04-04-2024
By GuruFocus Research • 03-22-2024
By GuruFocus News • 10-09-2024
By Business Wire • 02-12-2024
By GuruFocus Research • 05-15-2024
By Business Wire • 08-07-2024
By Business Wire • 09-18-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.